Head and Neck Pathology

, Volume 11, Issue 1, pp 55–67 | Cite as

Update from the 4th Edition of the World Health Organization Classification of Head and Neck Tumours: Tumors of the Salivary Gland

Original Paper
Part of the following topical collections:
  1. World Health Organization Classification Update

Abstract

The salivary gland section in the 4th edition of the World Health Organization classification of head and neck tumors features the description and inclusion of several entities, the most significant of which is represented by (mammary analogue) secretory carcinoma. This entity was extracted mainly from acinic cell carcinoma based on recapitulation of breast secretory carcinoma and a shared ETV6-NTRK3 gene fusion. Also new is the subsection of “Other epithelial lesions,” for which key entities include sclerosing polycystic adenosis and intercalated duct hyperplasia. Many entities have been compressed into their broader categories given clinical and morphologic similarities, or transitioned to a different grouping as was the case with low-grade cribriform cystadenocarcinoma reclassified as intraductal carcinoma (with the applied qualifier of low-grade). Specific grade has been removed from the names of the salivary gland entities such as polymorphous adenocarcinoma, providing pathologists flexibility in assigning grade and allowing for recognition of a broader spectrum within an entity. Cribriform adenocarcinoma of (minor) salivary gland origin continues to be divisive in terms of whether it should be recognized as a distinct category. This chapter also features new key concepts such as high-grade transformation. The new paradigm of translocations and gene fusions being common in salivary gland tumors is featured heavily in this chapter.

Keywords

World Health Organization Salivary gland Translocations Molecular Correlative Neoplasia Classification 

References

  1. 1.
    Eveson JW, Auclair PL, Gnepp DR, El-Naggar AK. Tumours of the salivary gland. In: Barnes L, Eveson JW, Reichart P, Sidransky D, (Eds.). World Health Organization classification of tumours: pathology and genetics of head and neck tumours. Lyon: IARC; 2005. p. 164.Google Scholar
  2. 2.
    Stenman G. Fusion oncogenes in salivary gland tumors: molecular and clinical consequences. Head Neck Pathol. 2013;7(Suppl 1):S12–9. doi:10.1007/s12105-013-0462-z.CrossRefPubMedGoogle Scholar
  3. 3.
    Chiosea SI, Griffith C, Assaad A, Seethala RR. The profile of acinic cell carcinoma after recognition of mammary analog secretory carcinoma. Am J Surg Pathol. 2012;36(3):343–50. doi:10.1097/PAS.0b013e318242a5b0.CrossRefPubMedGoogle Scholar
  4. 4.
    Skalova A, Vanecek T, Sima R, Laco J, Weinreb I, Perez-Ordonez B, et al. Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity. Am J Surg Pathol. 2010;34(5):599–608. doi:10.1097/PAS.0b013e3181d9efcc.PubMedGoogle Scholar
  5. 5.
    Bishop JA, Yonescu R, Batista D, Eisele DW, Westra WH. Most nonparotid “acinic cell carcinomas” represent mammary analog secretory carcinomas. Am J Surg Pathol. 2013;37(7):1053–7. doi:10.1097/PAS.0b013e3182841554.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Chenevert J, Duvvuri U, Chiosea S, Dacic S, Cieply K, Kim J, et al. DOG1: a novel marker of salivary acinar and intercalated duct differentiation. Mod Pathol. 2012;25(7):919–29. doi:10.1038/modpathol.2012.57.CrossRefPubMedGoogle Scholar
  7. 7.
    Skalova A, Vanecek T, Simpson RH, Laco J, Majewska H, Baneckova M, et al. Mammary analogue secretory carcinoma of salivary glands: molecular analysis of 25 ETV6 gene rearranged tumors with lack of detection of classical ETV6-NTRK3 fusion transcript by standard RT-PCR: report of 4 cases harboring ETV6-X gene fusion. Am J Surg Pathol. 2016;40(1):3–13. doi:10.1097/PAS.0000000000000537.CrossRefPubMedGoogle Scholar
  8. 8.
    Chiosea SI, Griffith C, Assaad A, Seethala RR. Clinicopathological characterization of mammary analogue secretory carcinoma of salivary glands. Histopathology. 2012;61(3):387–94. doi:10.1111/j.1365-2559.2012.04232.x.CrossRefPubMedGoogle Scholar
  9. 9.
    Skalova A, Vanecek T, Majewska H, Laco J, Grossmann P, Simpson RH, et al. Mammary analogue secretory carcinoma of salivary glands with high-grade transformation: report of 3 cases with the ETV6-NTRK3 gene fusion and analysis of TP53, beta-catenin, EGFR, and CCND1 genes. Am J Surg Pathol. 2014;38(1):23–33. doi:10.1097/PAS.0000000000000088.CrossRefPubMedGoogle Scholar
  10. 10.
    Drilon A, Li G, Dogan S, Gounder M, Shen R, Arcila M, et al. What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC). Ann Oncol. 2016;27(5):920–6. doi:10.1093/annonc/mdw042.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Smith BC, Ellis GL, Slater LJ, Foss RD. Sclerosing polycystic adenosis of major salivary glands. A clinicopathologic analysis of nine cases. Am J Surg Pathol. 1996;20(2):161–70.CrossRefPubMedGoogle Scholar
  12. 12.
    Skalova A, Gnepp DR, Simpson RH, Lewis JE, Janssen D, Sima R, et al. Clonal nature of sclerosing polycystic adenosis of salivary glands demonstrated by using the polymorphism of the human androgen receptor (HUMARA) locus as a marker. Am J Surg Pathol. 2006;30(8):939–44.CrossRefPubMedGoogle Scholar
  13. 13.
    Skalova A, Michal M, Simpson RH, Starek I, Pradna J, Pfaltz M. Sclerosing polycystic adenosis of parotid gland with dysplasia and ductal carcinoma in situ. Report of three cases with immunohistochemical and ultrastructural examination. Virchows Arch. 2002;440(1):29–35.CrossRefPubMedGoogle Scholar
  14. 14.
    Canas Marques R, Felix A. Invasive carcinoma arising from sclerosing polycystic adenosis of the salivary gland. Virchows Arch. 2014;464(5):621–5. doi:10.1007/s00428-014-1551-4.CrossRefPubMedGoogle Scholar
  15. 15.
    Weinreb I, Seethala RR, Hunt JL, Chetty R, Dardick I, Perez-Ordonez B. Intercalated duct lesions of salivary gland: a morphologic spectrum from hyperplasia to adenoma. Am J Surg Pathol. 2009;33(9):1322–9. doi:10.1097/PAS.0b013e3181a55c15.CrossRefPubMedGoogle Scholar
  16. 16.
    Montalli VA, Martinez E, Tincani A, Martins A, Abreu Mdo C, Neves C, et al. Tubular variant of basal cell adenoma shares immunophenotypical features with normal intercalated ducts and is closely related to intercalated duct lesions of salivary gland. Histopathology. 2014;64(6):880–9. doi:10.1111/his.12339.CrossRefPubMedGoogle Scholar
  17. 17.
    Chetty R. Intercalated duct hyperplasia: possible relationship to epithelial-myoepithelial carcinoma and hybrid tumours of salivary gland. Histopathology. 2000;37(3):260–3.CrossRefPubMedGoogle Scholar
  18. 18.
    Brandwein MS, Huvos AG. Oncocytic tumors of major salivary glands. A study of 68 cases with follow-up of 44 patients. Am J Surg Pathol. 1991;15(6):514–28.CrossRefPubMedGoogle Scholar
  19. 19.
    McHugh JB, Hoschar AP, Dvorakova M, Parwani AV, Barnes EL, Seethala RR. p63 immunohistochemistry differentiates salivary gland oncocytoma and oncocytic carcinoma from metastatic renal cell carcinoma. Head Neck Pathol. 2007;1(2):123–31. doi:10.1007/s12105-007-0031-4.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Daniels TE. Benign lymphoepithelial lesion and Sjögren’s syndrome. In: Ellis GL, Auclair PL, Gnepp DR, (Eds.). Surgical pathology of the salivary glands. Philadelphia: W.B. Saunders Company; 1991. p. 83–106.Google Scholar
  21. 21.
    Kreisel FH, Frater JL, Hassan A, El-Mofty SK. Cystic lymphoid hyperplasia of the parotid gland in HIV-positive and HIV-negative patients: quantitative immunopathology. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;109(4):567–74. doi:10.1016/j.tripleo.2009.12.008.CrossRefPubMedGoogle Scholar
  22. 22.
    Abbondanzo SL. Extranodal marginal-zone B-cell lymphoma of the salivary gland. Ann Diagn Pathol. 2001;5(4):246–54. doi:10.1053/adpa.2001.26980.CrossRefPubMedGoogle Scholar
  23. 23.
    Agaimy A, Ihrler S, Markl B, Lell M, Zenk J, Hartmann A, et al. Lipomatous salivary gland tumors: a series of 31 cases spanning their morphologic spectrum with emphasis on sialolipoma and oncocytic lipoadenoma. Am J Surg Pathol. 2013;37(1):128–37. doi:10.1097/PAS.0b013e31826731e0.CrossRefPubMedGoogle Scholar
  24. 24.
    Erickson-Johnson MR, Chou MM, Evers BR, Roth CW, Seys AR, Jin L, et al. Nodular fasciitis: a novel model of transient neoplasia induced by MYH9-USP6 gene fusion. Lab Invest. 2011;91(10):1427–33. doi:10.1038/labinvest.2011.118.CrossRefPubMedGoogle Scholar
  25. 25.
    Brandwein-Gensler MS, Gnepp DR. Low Grade Cribriform Cystadenocarcinoma. In: Barnes L, Eveson JW, Reichart P, Sidransky D, editors. World Health Organization classification of tumours: pathology and genetics of head and neck tumours. Lyon: IARC; 2005. p. 233.Google Scholar
  26. 26.
    Gnepp DR, Cheuk W, Chan JKC, Nagao T. Lymphadenomas: Sebaceous and Non-Sebaceous. In: Barnes L, Eveson JW, Reichart P, Sidransky D, (Eds.). World Health Organization classification of tumours: pathology and genetics of head and neck tumours. Lyon: IARC; 2005. p. 269.Google Scholar
  27. 27.
    Brannon RB, Sciubba JJ. Ductal Papillomas. In: Barnes L, Eveson JW, Reichart P, Sidransky D, (Eds.). World Health Organization classification of tumours: pathology and genetics of head and neck tumours. Lyon: IARC; 2005. pp. 270–2.Google Scholar
  28. 28.
    Seethala RR, Thompson LD, Gnepp DR, Barnes EL, Skalova A, Montone K, et al. Lymphadenoma of the salivary gland: clinicopathological and immunohistochemical analysis of 33 tumors. Mod Pathol. 2012;25(1):26–35. doi:10.1038/modpathol.2011.135.CrossRefPubMedGoogle Scholar
  29. 29.
    Brannon RB, Sciubba JJ, Giulani M. Ductal papillomas of salivary gland origin: a report of 19 cases and a review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001;92(1):68–77. doi:10.1067/moe.2001.115978.CrossRefPubMedGoogle Scholar
  30. 30.
    Auclair PL. Cystadenocarcinoma. In: Barnes L, Eveson JW, Reichart P, Sidransky D, (Eds.). World Health Organization classification of tumours: pathology and genetics of head and neck tumours. Lyon: IARC; 2005. p. 232.Google Scholar
  31. 31.
    Sun KH, Gao Y, Li TJ Mucinous Adenocarcinoma. In: Barnes L, Eveson JW, Reichart P, Sidransky D, (Eds.). World Health Organization classification of tumours: pathology and genetics of head and neck tumours. Lyon: IARC; 2005. pp. 233–4.Google Scholar
  32. 32.
    Gnepp DR. Malignant Sebaceous Tumours. In: Barnes L, Eveson JW, Reichart P, Sidransky D, (Eds.). World Health Organization classification of tumours: pathology and genetics of head and neck tumours. Lyon: IARC; 2005. p. 231.Google Scholar
  33. 33.
    Bradley PJ. ‘Metastasizing pleomorphic salivary adenoma’ should now be considered a low-grade malignancy with a lethal potential. Curr Opin Otolaryngol Head Neck Surg. 2005;13(2):123–6.CrossRefPubMedGoogle Scholar
  34. 34.
    Evans HL, Batsakis JG. Polymorphous low-grade adenocarcinoma of minor salivary glands. A study of 14 cases of a distinctive neoplasm. Cancer. 1984;53(4):935–42.CrossRefPubMedGoogle Scholar
  35. 35.
    Castle JT, Thompson LD, Frommelt RA, Wenig BM, Kessler HP. Polymorphous low grade adenocarcinoma: a clinicopathologic study of 164 cases. Cancer. 1999;86(2):207–19.CrossRefPubMedGoogle Scholar
  36. 36.
    Evans HL, Luna MA. Polymorphous low-grade adenocarcinoma: a study of 40 cases with long-term follow up and an evaluation of the importance of papillary areas. Am J Surg Pathol. 2000;24(10):1319–28.CrossRefPubMedGoogle Scholar
  37. 37.
    Seethala RR, Johnson JT, Barnes EL, Myers EN. Polymorphous low-grade adenocarcinoma: the University of Pittsburgh experience. Arch Otolaryngol Head Neck Surg. 2010;136(4):385–92. doi:10.1001/archoto.2010.39.CrossRefPubMedGoogle Scholar
  38. 38.
    Rooper L, Sharma R, Bishop JA. Polymorphous low grade adenocarcinoma has a consistent p63+/p40- immunophenotype that helps distinguish it from adenoid cystic carcinoma and cellular pleomorphic adenoma. Head Neck Pathol. 2015;9(1):79–84. doi:10.1007/s12105-014-0554-4.CrossRefPubMedGoogle Scholar
  39. 39.
    Skalova A, Sima R, Kaspirkova-Nemcova J, Simpson RH, Elmberger G, Leivo I, et al. Cribriform adenocarcinoma of minor salivary gland origin principally affecting the tongue: characterization of new entity. Am J Surg Pathol. 2011;35(8):1168–76. doi:10.1097/PAS.0b013e31821e1f54.CrossRefPubMedGoogle Scholar
  40. 40.
    Michal M, Skalova A, Simpson RH, Raslan WF, Curik R, Leivo I, et al. Cribriform adenocarcinoma of the tongue: a hitherto unrecognized type of adenocarcinoma characteristically occurring in the tongue. Histopathology. 1999;35(6):495–501.CrossRefPubMedGoogle Scholar
  41. 41.
    Simpson RH, Pereira EM, Ribeiro AC, Abdulkadir A, Reis-Filho JS. Polymorphous low-grade adenocarcinoma of the salivary glands with transformation to high-grade carcinoma. Histopathology. 2002;41(3):250–9.CrossRefPubMedGoogle Scholar
  42. 42.
    Weinreb I, Zhang L, Tirunagari LM, Sung YS, Chen CL, Perez-Ordonez B, et al. Novel PRKD gene rearrangements and variant fusions in cribriform adenocarcinoma of salivary gland origin. Genes Chromosomes Cancer. 2014;53(10):845–56. doi:10.1002/gcc.22195.CrossRefPubMedGoogle Scholar
  43. 43.
    Weinreb I, Piscuoglio S, Martelotto LG, Waggott D, Ng CK, Perez-Ordonez B, et al. Hotspot activating PRKD1 somatic mutations in polymorphous low-grade adenocarcinomas of the salivary glands. Nat Genet. 2014;46(11):1166–9. doi:10.1038/ng.3096.CrossRefPubMedGoogle Scholar
  44. 44.
    Weinreb I, Chiosea SI, Seethala RR, Reis-Filho JS, Weigelt B, Piscuoglio S, et al. Genotypic and phenotypic comparison of polymorphous and cribriform adenocarcinomas of salivary gland. Mod Pathol. 2015;28(S2):333.Google Scholar
  45. 45.
    Goode RK, El-Naggar AK Mucoepidermoid Carcinoma. In: Barnes L, Eveson JW, Reichart P, Sidransky D, (Eds.) World Health Organization classification of tumours: pathology and genetics of head and neck tumours. Lyon: IARC; 2005. pp. 219–20.Google Scholar
  46. 46.
    Goode RK, Auclair PL, Ellis GL. Mucoepidermoid carcinoma of the major salivary glands: clinical and histopathologic analysis of 234 cases with evaluation of grading criteria. Cancer. 1998;82(7):1217–24.CrossRefPubMedGoogle Scholar
  47. 47.
    Brandwein MS, Ivanov K, Wallace DI, Hille JJ, Wang B, Fahmy A, et al. Mucoepidermoid carcinoma: a clinicopathologic study of 80 patients with special reference to histological grading. Am J Surg Pathol. 2001;25(7):835–45.CrossRefPubMedGoogle Scholar
  48. 48.
    Batsakis JG, Luna MA. Histopathologic grading of salivary gland neoplasms: I. Mucoepidermoid carcinomas. Ann Otol Rhinol Laryngol. 1990;99(10 Pt 1):835–8.CrossRefPubMedGoogle Scholar
  49. 49.
    Katabi N, Ghossein R, Ali S, Dogan S, Klimstra D, Ganly I. Prognostic features in mucoepidermoid carcinoma of major salivary glands with emphasis on tumour histologic grading. Histopathology. 2014;65(6):793–804. doi:10.1111/his.12488.CrossRefPubMedGoogle Scholar
  50. 50.
    Seethala RR, Dacic S, Cieply K, Kelly LM, Nikiforova MN. A reappraisal of the MECT1/MAML2 translocation in salivary mucoepidermoid carcinomas. Am J Surg Pathol. 2010;34(8):1106–21. doi:10.1097/PAS.0b013e3181de3021.CrossRefPubMedGoogle Scholar
  51. 51.
    Costa AF, Altemani A, Hermsen M. Current concepts on dedifferentiation/high-grade transformation in salivary gland tumors. Patholog Res Int. 2011;2011:325965. doi:10.4061/2011/325965.PubMedPubMedCentralGoogle Scholar
  52. 52.
    Roy P, Bullock MJ, Perez-Ordonez B, Dardick I, Weinreb I. Epithelial-myoepithelial carcinoma with high grade transformation. Am J Surg Pathol. 2010;34(9):1258–65. doi:10.1097/PAS.0b013e3181e366d2.CrossRefPubMedGoogle Scholar
  53. 53.
    Williams L, Thompson LD, Seethala RR, Weinreb I, Assaad AM, Tuluc M, et al. Salivary duct carcinoma: the predominance of apocrine morphology, prevalence of histologic variants, and androgen receptor expression. Am J Surg Pathol. 2015;39(5):705–13. doi:10.1097/PAS.0000000000000413.CrossRefPubMedGoogle Scholar
  54. 54.
    Lewis JE, Olsen KD, Sebo TJ. Carcinoma ex pleomorphic adenoma: pathologic analysis of 73 cases. Hum Pathol. 2001;32(6):596–604. doi:10.1053/hupa.2001.25000.CrossRefPubMedGoogle Scholar
  55. 55.
    LiVolsi VA, Perzin KH. Malignant mixed tumors arising in salivary glands. I. Carcinomas arising in benign mixed tumors: a clinicopathologic study. Cancer. 1977;39(5):2209–30.CrossRefPubMedGoogle Scholar
  56. 56.
    Katabi N, Ghossein R, Ho A, Dogan S, Zhang L, Sung YS, et al. Consistent PLAG1 and HMGA2 abnormalities distinguish carcinoma ex-pleomorphic adenoma from its de novo counterparts. Hum Pathol. 2015;46(1):26–33. doi:10.1016/j.humpath.2014.08.017.CrossRefPubMedGoogle Scholar
  57. 57.
    Katabi N, Gomez D, Klimstra DS, Carlson DL, Lee N, Ghossein R. Prognostic factors of recurrence in salivary carcinoma ex pleomorphic adenoma, with emphasis on the carcinoma histologic subtype: a clinicopathologic study of 43 cases. Hum Pathol. 2010;41(7):927–34. doi:10.1016/j.humpath.2009.12.011.CrossRefPubMedGoogle Scholar
  58. 58.
    Gnepp DR, Brandwein-Gensler MS, el-Naggar AK, Nagao T. Carcinoma ex Pleomorphic Adenoma. In: Barnes L, Eveson JW, Reichart P, Sidransky D, (Eds.) World Health Organization classification of tumours: pathology and genetics of head and neck tumours. Lyon: IARC; 2005. pp. 242–3.Google Scholar
  59. 59.
    Di Palma S. Carcinoma ex pleomorphic adenoma, with particular emphasis on early lesions. Head Neck Pathol. 2013;7(Suppl 1):S68–76. doi:10.1007/s12105-013-0454-z.CrossRefPubMedGoogle Scholar
  60. 60.
    Griffith CC, Thompson LD, Assaad A, Purgina BM, Lai C, Bauman JE, et al. Salivary duct carcinoma and the concept of early carcinoma ex pleomorphic adenoma. Histopathology. 2014;65(6):854–60. doi:10.1111/his.12454.CrossRefPubMedGoogle Scholar
  61. 61.
    Weiler C, Zengel P, van der Wal JE, Guntinas-Lichius O, Schwarz S, Harrison JD, et al. Carcinoma ex pleomorphic adenoma with special reference to the prognostic significance of histological progression: a clinicopathological investigation of 41 cases. Histopathology. 2011;59(4):741–50. doi:10.1111/j.1365-2559.2011.03937.x.CrossRefPubMedGoogle Scholar
  62. 62.
    Brandwein-Gensler M, Hille J, Wang BY, Urken M, Gordon R, Wang LJ, et al. Low-grade salivary duct carcinoma: description of 16 cases. Am J Surg Pathol. 2004;28(8):1040–4.CrossRefPubMedGoogle Scholar
  63. 63.
    Simpson RH, Desai S, Di Palma S. Salivary duct carcinoma in situ of the parotid gland. Histopathology. 2008;53(4):416–25. doi:10.1111/j.1365-2559.2008.03135.x.CrossRefPubMedGoogle Scholar
  64. 64.
    Persson M, Andren Y, Mark J, Horlings HM, Persson F, Stenman G. Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck. Proc Natl Acad Sci USA. 2009;106(44):18740–4. doi:10.1073/pnas.0909114106.CrossRefPubMedPubMedCentralGoogle Scholar
  65. 65.
    Tonon G, Modi S, Wu L, Kubo A, Coxon AB, Komiya T, et al. t(11;19)(q21;p13) translocation in mucoepidermoid carcinoma creates a novel fusion product that disrupts a Notch signaling pathway. Nat Genet. 2003;33(2):208–13. doi:10.1038/ng1083.CrossRefPubMedGoogle Scholar
  66. 66.
    Jo VY, Sholl LM, Krane JF. Distinctive patterns of CTNNB1 (beta-Catenin) alterations in salivary gland basal cell adenoma and basal cell adenocarcinoma. Am J Surg Pathol. 2016;40(8):1143–50. doi:10.1097/PAS.0000000000000669.CrossRefPubMedGoogle Scholar
  67. 67.
    Persson F, Andren Y, Winnes M, Wedell B, Nordkvist A, Gudnadottir G, et al. High-resolution genomic profiling of adenomas and carcinomas of the salivary glands reveals amplification, rearrangement, and fusion of HMGA2. Genes Chromosomes Cancer. 2009;48(1):69–82. doi:10.1002/gcc.20619.CrossRefPubMedGoogle Scholar
  68. 68.
    Andersson MK, Stenman G. The landscape of gene fusions and somatic mutations in salivary gland neoplasms - Implications for diagnosis and therapy. Oral Oncol. 2016;57:63–9. doi:10.1016/j.oraloncology.2016.04.002.CrossRefPubMedGoogle Scholar
  69. 69.
    Antonescu CR, Katabi N, Zhang L, Sung YS, Seethala RR, Jordan RC, et al. EWSR1-ATF1 fusion is a novel and consistent finding in hyalinizing clear-cell carcinoma of salivary gland. Genes Chromosomes Cancer. 2011;50(7):559–70. doi:10.1002/gcc.20881.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  1. 1.Department of Pathology and Laboratory MedicineUniversity of PittsburghPittsburghUSA
  2. 2.Department of Pathology and Genetics, Sahlgrenska Cancer CenterUniversity of GothenburgGothenburgSweden

Personalised recommendations